Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
NCT02057172 on ClinicalTrials.gov · last registry update 2016-08-09
An unusually large phase 2: 254 participants, more than double the 110 typical for the stage. The sponsor logged completion for October 2014. Primary outcome, as filed: Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Sponsor type
- Industry
- Enrollment
- 254
- Started
- 2014-01
- Primary completion
- 2014-10 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.